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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. 2 
SARS-CoV-2 relies on cellular RNA-binding proteins (RBPs) to replicate and spread, 3 
although which RBPs control its life cycle remains largely unknown. Here, we employ a 4 
multi-omic approach to identify systematically and comprehensively the cellular and viral 5 
RBPs that are involved in SARS-CoV-2 infection. We reveal that SARS-CoV-2 infection 6 
profoundly remodels the cellular RNA-bound proteome, which includes wide-ranging 7 
effects on RNA metabolic pathways, non-canonical RBPs and antiviral factors. 8 
Moreover, we apply a new method to identify the proteins that directly interact with viral 9 
RNA, uncovering dozens of cellular RBPs and six viral proteins. Amongst them, several 10 
components of the tRNA ligase complex, which we show regulate SARS-CoV-2 11 
infection. Furthermore, we discover that available drugs targeting host RBPs that 12 
interact with SARS-CoV-2 RNA inhibit infection. Collectively, our results uncover a new 13 
universe of host-virus interactions with potential for new antiviral therapies against 14 
COVID-19. 15 
INTRODUCTION 16 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, 17 
China, probably because of zoonotic transmission from bats (Zhou et al., 2020). It is the 18 
causative agent of coronavirus disease 2019 (COVID-19), and has become a pandemic 19 
(Dong et al., 2020). SARS-CoV-2 belongs to the Coronaviridae family, and has a single-20 
stranded, positive-sense RNA genome of ~30kb. It is an intracellular parasite that relies 21 
on host cell resources to replicate and spread. Hence, intensive efforts have been 22 
undertaken to improve our understanding of SARS-CoV-2 interactions with the host cell 23 
(Banerjee et al., 2020; Bojkova et al., 2020; Bouhaddou et al., 2020; Gordon et al., 2020; 24 
Kim et al., 2020b; Klann et al., 2020; Stukalov et al., 2020). 25 
Most of the processes of the life cycle of RNA viruses are directed to multiply, transport 26 
and deliver the viral RNA genome into a new cell. However, these viral genomes cannot 27 
encode all the proteins required to accomplish these processes autonomously and to 28 
overcome this limitation viruses hijack cellular RNA-binding proteins (RBPs) (Dicker et 29 
al., 2020; Garcia-Moreno et al., 2018). In response, the host cell employs specialised 30 











unusual molecular signatures, including tri-phosphate ends, undermethylated cap and 1 
double stranded (ds)RNA (Habjan and Pichlmair, 2015). RBP sensing of viral RNA 2 
triggers the cellular antiviral state, which can suppress viral gene expression through the 3 
inhibition of protein synthesis and the production of interferons. Therefore, cellular RBPs 4 
are key regulators of the virus life cycle, either promoting or restricting infection (Garcia-5 
Moreno et al., 2018; Habjan and Pichlmair, 2015). It is thus fundamental to elucidate the 6 
interactions that SARS-CoV-2 RNA establishes with the host cell.  7 
We recently developed comparative RNA interactome capture (cRIC) to discover how 8 
the RNA-bound proteome (RBPome) responds to the Sindbis (SINV) infection (Garcia-9 
Moreno et al., 2019). Our studies showed that SINV infection remodels the cellular 10 
RBPome and that these changes are critical for viral fitness (Garcia-Moreno et al., 11 
2019). These observations further highlight the essential role that RBPs play in 12 
regulating the viral life cycle (Dicker et al., 2020; Garcia-Moreno et al., 2018). In the last 13 
few years, several approaches have been developed to identify the cellular proteins that 14 
interact with viral RNA (Kim et al., 2020a; LaPointe et al., 2018; Ooi et al., 2019; Phillips 15 
et al., 2016; Viktorovskaya et al., 2016). While these studies make important advances 16 
towards the understanding of viral ribonucleoproteins (RNPs), the choice of crosslinking 17 
and RNA isolation approaches may impact the results. For example, while formaldehyde 18 
is a more efficient crosslinker than ultraviolet light (UV), it also promotes protein-protein 19 
crosslinks allowing the capture of indirect interactions through protein-protein bridges 20 
(Tayri-Wilk et al., 2020). Despite their pros and cons, these studies discovered cellular 21 
proteins that engage with viral RNA in infected cells, revealing that the viral RNA is a 22 
hub for complex host-virus interactions (Kim et al., 2020a; Knoener et al., 2017; 23 
LaPointe et al., 2018; Ooi et al., 2019; Phillips et al., 2016; Schmidt et al., 2020; 24 
Viktorovskaya et al., 2016).  25 
In this study, we employ multiple proteome-wide approaches to discover the role of 26 
RBPs in SARS-CoV-2 life cycle. We discover that the repertoire of cellular RBPs widely 27 
remodels in response to SARS-CoV-2 infection, affecting proteins involved in RNA 28 
metabolism, antiviral defences and other pathways. Moreover, we identify the cellular 29 
and viral proteins that interact with SARS-CoV-2 RNAs employing a new approach 30 
named viral RNA interactome capture (vRIC). Dozens of cellular RBPs and six viral 31 












infection. Furthermore, we show that pharmacological inhibition or dysregulation of 1 
cellular RBPs that interact with viral RNA impairs SARS-CoV-2 infection. Collectively, 2 
our data uncover the landscape of protein-RNA interactions that regulate SARS-CoV-2 3 
infection and provide new targets for the discovery of novel anti-viral treatments against 4 
COVID-19. 5 
RESULTS AND DISCUSSION 6 
The cellular RNA-binding proteome globally responds  to SARS-CoV-2 infection 7 
Cellular RBPs are fundamental for viruses, as they can promote or supress infection. To 8 
elucidate the landscape of active RBPs in SARS-CoV-2 infected cells, we used cRIC 9 
(Garcia-Moreno et al., 2019). In brief, cRIC employs ‘zero distance’, ultraviolet (UV) 10 
protein-RNA crosslinking, followed by denaturing lysis, oligo(dT) selection of 11 
polyadenylated [poly(A)] RNA and quantitative proteomics (Garcia-Moreno et al., 2019; 12 
Perez-Perri et al., 2020b; Sysoev et al., 2016). To determine the optimal conditions for 13 
these experiments, we performed infection kinetics in epithelial human lung cancer cells 14 
(Calu-3). SARS-CoV-2 RNA and infective particles increase over time and peak at 24 15 
hours post infection (hpi) (Figure 1B-C and S1A). Subsequently, cell numbers sharply 16 
decrease from 36 hpi, suggesting widespread cell death (Figure 1D). We thus chose two 17 
stages of the viral lifecycle: 1) an early timepoint where viral RNA is exponentially 18 
increasing (8 hpi), and 2) a late timepoint where viral RNA and extracellular virions peak 19 
(24 hpi), prior to cell death induction. cRIC was then applied to SARS-CoV-2 infected (8 20 
and 24 hpi) and uninfected cells (Figure 1A). We identified a total of 809 proteins; 86% 21 
of which are annotated by the gene ontology term ‘RNA-binding’ and are enriched in 22 
well-established RNA-binding domains, resembling previously established RBPomes 23 
(Figure 1E-F, S1B and Table S1) (Hentze et al., 2018). 70 proteins displayed changes 24 
greater than 2-fold at 8 hpi, although only 5 qualified as statistically significant (Figure 25 
1G and Table S1). This suggests that early RBP responses are either subtle or are 26 
variable across replicates. Conversely, 335 RBPs were significantly altered at 24 hpi. Of 27 
these, 176 showed increased and 159 decreased RNA-binding activity (Figure 1G and 28 
Table S1). Importantly, SARS-CoV-2-regulation affects both classical RBPs and 29 
unorthodox RBPs lacking known RNA-binding domains (RBDs) (Figure 1F). Moreover, 30 
regulated RBPs, and especially those stimulated by SARS-CoV-2, include proteins 31 












immunity (Figure S1C).  Together, these results reveal that SARS-CoV-2 infection 1 
initially causes a subtle remodelling of the cellular RBPome (8 hpi) that becomes 2 
pervasive by 24hpi. Interestingly, cRIC also identified three viral RBPs at 8 hpi and five 3 
at 24 hpi (Figure 1G). These include known viral RBPs such as nucleocapsid (NCAP) 4 
and the polyprotein ORF1a/b, as well as proteins not known to interact with RNA such 5 
as M, S and ORF9b. 6 
Potential causes for SARS-CoV-2 induced RBPome remo delling 7 
We hypothesised that the remodelling of the RBPome induced by SARS-CoV-2 can 8 
simply be a consequence of changes in protein abundance, as previously reported for 9 
fruit fly embryo development (Sysoev et al., 2016). To assess this possibility, we 10 
analysed the whole cell proteome (WCP) of SARS-CoV-2 infected and uninfected cells 11 
(Figure 2A-B, S2A-C and Table S2). 69 and 222 proteins out of the 4555 quantified 12 
exhibited significant changes in abundance at 8 and 24 hpi, respectively (Figure 2A, 13 
S2D and Table S2). As expected, all viral proteins increased in abundance as infection 14 
progressed (Figure 2A). The WCP analysis covers 82% of the proteins identified by 15 
cRIC, providing a broad overview on RBP levels in infected and uninfected cells. When 16 
cRIC and WCP were compared we observed correlation only for viral proteins and a few 17 
cellular proteins (Figure 2B). This reflects that the capture of viral proteins by RIC 18 
increases as viral proteins accumulate. Conversely, changes in cRIC were not matched 19 
with similar changes in WCP for most RBPs (Figure 2B). These results stand when 20 
recently published WCP datasets were used (Klann et al., 2020; Stukalov et al., 2020), 21 
despite an increase of RBP coverage to 93% (Figure S2B-C). Lack of correlation 22 
between RBPome and WCP unequivocally indicates that protein abundance is not a 23 
global contributor to RBP responses in SARS-CoV-2 infected cells.  24 
RNA abundance can also influence the RBPome and so we analysed poly(A)-selected 25 
RNA sequencing data from Calu-3 cells infected with SARS-CoV-2 for 24h (Blanco-Melo 26 
et al., 2020) (Figure 2C-D and S2E-G). As expected, SARS-CoV-2 causes substantial 27 
alterations in the cellular transcriptome, with 5465 RNAs displaying significant fold 28 
changes when compared to the uninfected control (2733 upregulated and 2732 29 
downregulated with p<0.01; Figure 2C and S2E). Particularly, viral RNAs emerge as 30 
dominant poly(A) RNA species in the cell, representing 14-19% of the reads (Figure 2C 31 












abundant substrates for cellular RBPs and 2) that they are captured by oligo(dT) and 1 
must thus contribute to the changes observed by cRIC. Together, the alterations in 2 
cellular mRNA levels and the emergence of the viral RNA as the most abundant poly(A) 3 
RNA, likely have a major impact on the composition of the RBPome in SARS-CoV-2 4 
infected cells.  5 
Post-translational modifications (PTMs) are known to regulate RBPs (Arif et al., 2018; 6 
Castello et al., 2016). We hypothesise that SARS-CoV-2 induced PTMs can thus also 7 
affect RBP dynamics. To test this possibility, we used SARS-CoV-2 regulated PTMs 8 
from recently published datasets (Bouhaddou et al., 2020; Klann et al., 2020; Stukalov et 9 
al., 2020) and mapped these to cRIC-identified RBPs. Of the 335 RBPs regulated by 10 
SARS-CoV-2, 123 possessed differential phosphorylation sites and 62 differential 11 
ubiquitination sites (Table S3). Strikingly, these SARS-CoV-2-regulated PTMs occur 12 
more frequently in upregulated RBPs than in downregulated or unaltered RBPs (Figure 13 
2E), suggesting that PTMs could contribute to the RBP’s ability to interact with RNA. 14 
Indeed, we observed that SARS-CoV-2 modulated RBPs were more frequently 15 
phosphorylated at multiple sites than their unaltered counterparts (Figure S2H). These 16 
results suggest that posttranslational control may also contribute to the differential RNA-17 
binding activity observed for dozens of RBPs in SARS-CoV-2 infected cells. In summary, 18 
the combination of the changes in the transcriptome (Figure 2C-D), and post-19 
translational regulation (Figure 2E and Table S3) are likely contributing to the regulation 20 
of RBP activities reported here. 21 
Kinetics of RBP alterations upon SARS-CoV-2 infecti on  22 
The kinetics of RBP activation and inhibition can be informative for protein complex 23 
dynamics and function. To further characterise RBP responses after SARS-CoV-2 24 
infection, we clustered proteins based on their cRIC fold changes at 8 and 24 hpi. Our 25 
analysis distinguishes eight RBP response profiles (Figure 3A and Table S4). Clusters 2 26 
and 7 are dominant, with 114 proteins in each group, reflecting that most RBPs changes 27 
are only detected at 24 hpi. By contrast, 70 RBPs exhibited more complex RNA-binding 28 
patterns, distributing across clusters 1, 3, 4, 5, 6 and 8.  29 
SARS-CoV-2 RNAs accumulate throughout the infection, and proteins involved in viral 30 












comprised of RBPs whose RNA-binding activity increases throughout the infection. 1 
Apart from most viral RBPs, cluster 3 harbours several notable cellular factors that have 2 
either been linked to virus infection or are known to play critical roles in cellular 3 
pathways required for viruses. These include the antiviral protein GEMIN5 (Garcia-4 
Moreno et al., 2019; Martinez-Salas et al., 2020), the autophagy factor SQSTM1 (p62) 5 
(Horos et al., 2019), and the master regulator of virus infection PPIA (cyclophilin A) 6 
(Dawar et al., 2017).  7 
SQSTM1 (also p62) is a critical component of the autophagy pathway that plays a key 8 
role as a receptor of the autophagy substrates and mediates the interaction with growing 9 
phagophores to form autophagosomes (Buscher et al., 2020). In a recent report, it was 10 
shown that SQSTM1 is inhibited by interaction with vault (vt) RNA 1-1 (Horos et al., 11 
2019). The interaction of SQSTM1 with RNA is mediated by its ZZ and PB1 domain, and 12 
the resulting complex is unable to mediate autophagy. The strong increase in RNA-13 
binding activity of SQSTM1 upon SARS-CoV-2 infection suggests that autophagy is 14 
inhibited upon infection through this pathway. Interestingly, the vault complex, which 15 
contains vtRNAs, has been reported to reside in close proximity to the double-16 
membrane vesicles that are the sites of viral replication (Klein et al., 2020). However, 17 
whether the increase in SQSTM1 RNA-binding activity involves vtRNA1-1 or viral RNA 18 
requires further investigation. 19 
SARS-CoV-2 NSP1 inhibits protein synthesis by interacting with the ribosome’s mRNA 20 
channel (Banerjee et al., 2020; Schubert et al., 2020; Thoms et al., 2020). To determine 21 
how this inhibitory interaction affects cellular RBPs, we analysed the kinetic profiles of all 22 
proteins annotated by ‘translation’ and ‘ribosome’ GO terms. We observed the presence 23 
of several components of the eukaryotic initiation factor (EIF)3, EIF2S1 (also EIF2α), 24 
elongation factors and ribosomal proteins in clusters 4, 6, 7 and 8, which are comprised 25 
of downregulated RBPs (Figure 3A and B, S3A and B and Table S4). Conversely, the 26 
cap- and poly(A)-binding proteins eIF4E and PABPC1, as well as the other translation 27 
initiation factors such as EIF4A1 and EIF4A2, EIF4B and EIF4G1 and EIF4G3, are 28 
present in cluster 2, which is comprised of upregulated RBPs (Figure 3A and B, and 29 
Table S4). These opposed results support a model in which the cap- and poly(A)-binding 30 
factors can interact with cellular mRNAs but cannot associate with EIF3 and the 31 












recruitment to cellular mRNAs (Gehring et al., 2009; Schubert et al., 2020; Tidu et al., 1 
2020; Yi et al., 2020). 2 
If this model is correct, it is expected that the exon junction complex (EJC) would 3 
accumulate onto cellular mRNAs, as it is removed during the pioneering round of 4 
translation (Gehring et al., 2009; Yi et al., 2020). To test this hypothesis, we searched for 5 
the core components of the EJC in our dataset and observed that EIF4A3, RBM8A and 6 
CASC3 are upregulated in SARS-CoV-2 infected cells (also in cluster 2, Figure 3A and 7 
B and S3E). Conversely, the EJC removal factor WIBG (PYM1) (Gehring et al., 2009) is 8 
downregulated, further supporting that co-translational removal of EJCs is impaired in 9 
infected cells. Moreover, the crucial nonsense mediated decay factor UPF1 (cluster 7) is 10 
also inhibited upon infection, which reflects that co-translational quality control is not 11 
taking place efficiently. Collectively, these results indicate that SARS-CoV-2 induced 12 
protein synthesis shut off may cause the accumulation of matured transcripts into a 13 
translation-inactive state.  14 
Deposition of EJCs on cellular RNAs is a consequence of the splicing reaction (Yi et al., 15 
2020). However, a recent study reported that NSP16 interacts with the U1 and U2 small 16 
nuclear (sn)RNAs and disrupt splicing (Banerjee et al., 2020). To assess the effects of 17 
NSP16 in RBP dynamics we examined the cRIC fold changes of all spliceosome-18 
associated proteins. Surprisingly, the components of the core spliceosomal complexes 19 
showed no significant changes, except for SNRPG that was substantially upregulated 20 
(Figure S3D and Table S1). Conversely, several splicing factors showed strong changes 21 
in RNA-binding activity, including the branch point binder U2AF2, U2SURP, most 22 
serine/arginine (SR)-rich splicing factors (SRSF) and several HNRNPs (Figure S3D, E 23 
and F). Many of these proteins play important roles in exon and intron definition as well 24 
as in the recruitment of the spliceosome (Ule and Blencowe, 2019) and, in agreement, 25 
we observed 786 differentially used exons in 560 genes at 24 hpi (Figure S2G). These 26 
results suggest that the alterations in splicing factors induced by SARS-CoV-2 infection 27 
may cause substantial effects in alternative splicing. 28 
Comparison of SARS-CoV-2 and SINV induced alteratio ns of the RBPome  29 
To determine whether the changes that SARS-CoV-2 induces in the cellular RBPome 30 












(Garcia-Moreno et al., 2019). SINV is a positive stranded virus from the alphavirus 1 
genus. As SARS-CoV-2, SINV genome is capped and polyadenylated, although it is 2 
substantially smaller (~11kb vs ~30kb). Moreover, both viruses produce subgenomic 3 
RNAs and replicate in the cytoplasm. Strikingly, nearly 40% of the changes in RBP 4 
activity observed in SARS-CoV-2 were also present in the SINV cRIC dataset (Figure 5 
4A-C). This exciting result indicates that even if these viruses belong to different families 6 
and have little or no sequence homology, they cause similar alterations in the RBPome 7 
that are consistent for both upregulated and downregulated RBPs (Figure 4A and B). 8 
Several antiviral factors were noticeable amongst the 93 RBPs with consistent 9 
responses, TRIM25, TRIM56, ZC3HAV1 (also ZAP), DHX36 and GEMIN5 (Figure 4D 10 
and S4A). These antiviral RBPs are upregulated in both datasets, suggesting that they 11 
are likely involved in the antiviral response against both SARS-CoV-2 and SINV. 12 
TRIM25 is an E3 ubiquitin ligase whose catalytic activity is triggered by RNA binding and 13 
interacts with SINV RNA (Choudhury et al., 2017; Garcia-Moreno et al., 2019). TRIM25 14 
antiviral activity is thought to be mediated by the ubiquitination of RIGI and 15 
ZC3HAV1/ZAP (Gack et al., 2007; Li et al., 2017).  While RIGI was not detected in our 16 
analysis, ZC3HAV1/ZAP RNA-binding activity was also upregulated in response to 17 
infection, suggesting that it may be the effector activated by TRIM25. GEMIN5 is an 18 
antiviral factor that interacts with the cap and 5’UTR of SINV RNA and supresses viral 19 
mRNA translation (Garcia-Moreno et al., 2019; Martinez-Salas et al., 2020). Given that 20 
SARS-CoV-2 RNAs are also capped, it is thus plausible that GEMIN5 hampers SARS-21 
CoV-2 gene expression following a similar mechanism. Other RBPs with prominent roles 22 
in virus infection were consistently upregulated by SARS-CoV-2 and SINV, including 23 
PPIA (cyclophilin A), PA2G4, ZC3H11A, DDX3, and HSP90AB1 (Figure S4B) (Dawar et 24 
al., 2017; Garcia-Moreno et al., 2019; Valiente-Echeverria et al., 2015; Younis et al., 25 
2018).Our data also revealed antiviral RBPs that are downregulated by SARS-CoV-2 26 
and, in several instances, also by SINV. These include the RNA editing enzymes ADAR, 27 
APOBEC3F and APOBEC3G, and the nonsense mediated decay helicase UPF1 (Figure 28 
S4C).  29 
Interestingly, 12% of the proteins exhibited opposite behaviour in the two viral models. 30 
Many of these can be traced back to membraneless organelles such us paraspeckles 31 
and stress granules. The core paraspeckle components NONO, PSPC1, SFPQ and 32 












by SARS-CoV-2 (Figure 4D and S4D). It is proposed that paraspeckles are critical to 1 
sequester proteins and/or mRNAs to regulate gene expression, although the importance 2 
of paraspeckle proteins in virus infection remains poorly understood (Fox et al., 2018). 3 
Similar anticorrelation was observed with the stress granule proteins G3BP1 and G3BP2 4 
(Figure 4D and S4D). Stress granules play a defensive role against viruses by 5 
sequestering viral RNA (McCormick and Khaperskyy, 2017). Alphaviruses like SINV are 6 
known to supress stress granule formation, and this is accompanied by an increase of 7 
G3BP1 and G3BP2 RNA-binding activity (Garcia-Moreno et al., 2019; Kim et al., 2016; 8 
Panas et al., 2012; Scholte et al., 2015). The inhibition of G3BP1 and G3BP2 in SARS-9 
CoV-2 infected cells may thus reflect an opposite outcome, i.e. lower association with 10 
RNA due to the induction of stress granules.  11 
The SARS-CoV-2 RNA interactome 12 
cRIC captures both SARS-CoV-2 and cellular mRNAs, which represent 14-19% and 80-13 
84% of the eluted RNA, respectively (Figure 2D and S2F). Therefore, it is not possible to 14 
know a priori which of the observed protein-RNA interactions are driven by viral RNA. To 15 
systematically identify the RBPs that interact directly with SARS-CoV-2 RNAs, we 16 
applied a newly developed approach that we named viral RNA interactome capture 17 
(vRIC) (Figure 5A and B and S5A). In brief, SARS-CoV-2-infected and uninfected Calu-3 18 
cells are treated with the RNA polymerase II (RNAPII) specific inhibitor flavopiridol (Fvo), 19 
followed by a pulse with the photoactivatable nucleotide analogue 4-thiouridine (4SU). 20 
As viral RNA polymerases are insensitive to Fvo, temporal inhibition of RNAPII causes 21 
4SU to be predominantly incorporated into nascent viral RNAs. Cells are then UV 22 
irradiated at 365 nm to induce crosslinks between viral RNA and proteins placed at a 23 
‘zero distance’ from the 4SU molecules. As natural nucleotide bases do not absorb UV 24 
at 365 nm, protein-RNA crosslinking is restricted to 4SU-containing viral RNA. Cells are 25 
then lysed under denaturing conditions and poly(A)-containing RNA is captured with 26 
oligo(dT) following a previously designed robust procedure (Castello et al., 2012). After 27 
elution, proteins co-purified with the viral RNA are analysed by proteomics.  28 
Our control experiments showed that Fvo strongly abrogates RNAPII transcription from 29 
a strong tetracycline-inducible cytomegalovirus promoter, and that neither Fvo nor 4SU 30 
interfered with SARS-CoV-2 replication (Figure 5C and S5A-C). In mock cells, 4SU 31 












isolation of the steady state RBPome (Figure S5E-I). However, when 4SU was omitted 1 
or Fvo was added, the amount of protein co-isolated with RNA was massively reduced in 2 
both silver staining and proteomic analyses (Figure S5D, F and G). These results show 3 
that active RNAPII is required in uninfected cells to achieve efficient 4SU-dependent 4 
protein-RNA UV crosslinking. Conversely, when cells were infected with SARS-CoV-2, 5 
efficient protein isolation was observed despite Fvo treatment (Figure 5D-E and S5E-I). 6 
These findings confirm that 4SU incorporation into nascent viral RNAs promotes 7 
effective UV protein-RNA crosslinking at 365nm (Figure 5D-E and S5E-I). In agreement, 8 
a principal component analysis revealed that the datasets derived from uninfected and 9 
SARS-CoV-2 infected cells are clearly distinct (Figure 5D), with a total of 139 RBPs 10 
enriched in vRIC eluates from SARS-CoV-2 infected cells (SARS-CoV-2/4SU/Fvo) over 11 
the mock control (M/4SU/Fvo), 107 with 1% false discovery rate (FDR) and 32 additional 12 
proteins at 10% FDR (Figure 5E, Table S5). The SARS-CoV-2 mRNA interactome is 13 
enriched in proteins annotated by the GO term ‘RNA binding’ (89%) and harbouring 14 
known RBDs (65%) (Figure 5F-G), supporting the capacity of vRIC to identify bona fide 15 
protein-RNA interactions. The SARS-CoV-2 RNA interactome is enriched in GO terms 16 
associated RNA metabolism (RNA splicing, transport, stability, silencing and translation), 17 
antiviral response (e.g. RIGI pathway), cytoplasmic granule assembly (stress granules 18 
and P-bodies), and virus biology (e.g. viral process, dsRNA binding, IRES-dependent 19 
viral RNA translation) (Figure 5H). Notably, 8 and 9 proteins were annotated by innate 20 
immunity related terms in KEGG and GO, respectively (Figure 5I).  21 
Recently, a complementary SARS-CoV-2 RNA interactome has been generated in 22 
SARS-CoV-2 infected hepatoma (Huh-7) cells using RAP-MS, which combines UV 23 
crosslinking and specific antisense probes (Schmidt et al., 2020). Gratifyingly, this 24 
dataset overlaps well with our vRIC data despite being generated with different cell 25 
types (hepatocytes versus lung epithelial cells) and methods (RAP-MS versus vRIC) 26 
(Figure S5J). However, vRIC identified substantially more RBPs than RAP-MS at all 27 
FDR cut-offs tested, providing additional SARS-CoV-2 RNA interactors.   28 
To determine to what extent the SARS-CoV-2 RNA interactome harbours cellular RBPs 29 
that are also present in the RNPs of other viruses, we compared the SARS-CoV-2 vRIC 30 
to a SINV vRIC dataset generated in a parallel study (Kamel et al., In preparation). The 31 












starting material available (Figure S5K). Nevertheless, 60% of the RBPs within the 1 
SARS-CoV-2 RNA interactome were also present in that of SINV (Figure 5J). These 2 
striking results suggest that viral RNPs may share a larger proportion of cellular factors 3 
than previously anticipated, opening the possibility to target commonly used RBPs in 4 
broad-spectrum therapeutic approaches. 5 
The cRIC analysis revealed global alterations of the translation machinery (Figure 3B 6 
and S3A-B). To test if these alterations also apply SARS-CoV-2 RNAs, we examined the 7 
translation factors present in viral RNPs. Most of the proteins involved in the recognition 8 
of the cap and poly(A) tail are identified in SARS-CoV-2 RNP, including EIF4G1, 9 
EIF4G3, EIF4A1, EIF4A2, EIF4B and PABPC1 (Figure 5E and Table S5). However, one 10 
of the critical components is missing: the cap-binding protein EIF4E. While we cannot 11 
rule out that this missing protein is a false negative, other capped RNA viruses such as 12 
SINV can initiate translation without EIF4E, calling for further experiments to 13 
discriminate between these two possibilities (Carrasco et al., 2018). Moreover, several 14 
core EIF3 subunits (A, C, D and G) are highly enriched in the SARS-CoV-2 RNP, 15 
revealing that the molecular bridge connecting the ribosome and the mRNA (Merrick and 16 
Pavitt, 2018) is active in SARS-CoV-2 mRNAs despite the downregulation of several 17 
EIF3 subunits in the cRIC analysis (Figure 5E and Table S5). These results suggest that 18 
even though EIF3 subunits C and D have an overall reduced association with RNAs 19 
likely due to NSP1 action, they do interact with SARS-CoV-2 RNA to enable viral protein 20 
synthesis.  21 
cRIC revealed an upregulation of many HNRNPs (Figure S3F). To test if viral RNA is 22 
involved in these alterations, we examined the vRIC dataset. Notably, 10 HNRNPs 23 
interact with SARS-CoV-2 RNA, particularly from the A family (A0, A1, A2B1, A3, C, DL, 24 
M, L, Q [SYNCRIP] and R). Indeed, immunofluorescence analysis revealed that a 25 
subpopulation of HNRNPA1 accumulates at cytoplasmic viral dsRNA-containing foci 26 
(Figure S5L). These results suggest that the enhancement of HRNP RNA-binding 27 
activity may be driven by SARS-CoV-2 RNA accumulation.  28 
The cRIC analysis revealed a connection between SARS-CoV-2 infection and RNA 29 
granules (Figure 4D and S4D). To determine if such interplay involves the viral RNA, we 30 
searched for known components of RNA granules in the vRIC dataset. Notably, we 31 












interacting proteins CAPRIN1, NUFIP2 and USP10 within SARS-CoV-2 RNPs (Figure 1 
5E and Table S5). These results, together with the observed downregulation of G3BP1 2 
and G3BP2 (Figure 4D and S4D-E) and their interaction with the viral nucleocapsid 3 
(NCAP) (Gordon et al., 2020), reflect an intimate relationship between stress granules 4 
and SARS-CoV-2 RNAs. Additionally, the P-body components DDX6, LSM14A, PATL1 5 
and the miRNA mediator AGO2, also interact with SARS-CoV-2 mRNA. Conversely, 6 
none of the nuclear paraspeckle proteins were statistically enriched in the viral RNP, 7 
suggesting that their role in SARS-CoV-2 infection, if any, might be indirect. Collectively, 8 
our data shows that SARS-CoV-2 RNA engage with components of stress granules and 9 
P-bodies.  10 
SARS-CoV-2 RNA is post-transcriptionally edited, although the importance of this 11 
remains unknown (Kim et al., 2020b). To obtain more insights into this phenomenon and 12 
its consequences in the composition of the viral RNP, we searched for all ‘editors’ and 13 
‘readers’ that interact with SARS-CoV-2 RNAs (Table S5). ADAR is downregulated upon 14 
SINV infection (Table S1); however, it is highly enriched in SARS-CoV-2 RNPs (Figure 15 
5E and Table S5). It catalysed the conversion of adenosines to inosine, which can affect 16 
several aspects of RNA function, including structure, RBP binding sites and coding 17 
sequence, potentially regulating viral replication. The participation of ADAR in SARS-18 
CoV-2 infection is underscored by a recent study reporting adenosine deamination in the 19 
SARS-CoV-2 RNA (Di Giorgio et al., 2020). Methyl 6 adenosine (m6A) also plays critical 20 
roles in virus infection and viral RNA is typically enriched with this modification (Tan and 21 
Gao, 2018). m6A is recognised by a family of proteins known as ‘readers’, which 22 
regulate RNA fate (Wang et al., 2014). While the readers YTHDF2 and YTHDF3 are 23 
downregulated in both SINV and SARS-CoV-2 infected cells, YTHDC1 and YTHDC2 are 24 
stimulated (Figure 4D and S4F and G). These opposed results indicate that m6A 25 
readers are differentially regulated in response to infection. Our vRIC analysis shows 26 
that YTHDC2 is significantly enriched in the SARS-CoV-2 RNPs (Figure 5E, Table S5). 27 
These results support the potential role of YTHDC2, and perhaps YTHDC1, as 28 
mediators of m6A function in SARS-CoV-2 infection.  29 
Other noteworthy proteins that interact with SARS-CoV-2 RNA include five helicases 30 
(DDX1, DDX3X, DDX6, DDX60, DHX57); four chaperones (HSP90AA1, HSP90AB1, 31 











ligase MKRN2; the vesicle membrane protein VAT1 that interacts with M, ORF7b 1 
(NS7B) and ORF9b (Gordon et al., 2020); the antiviral protein OASL that belongs to a 2 
family of SARS-CoV-2 susceptibility factors (Pairo-Castineira et al., 2020), and three 3 
separate subunits of the protein phosphatase 1 (PPP1CA, PPP1CB, PPP1R3A), 4 
amongst others. Collectively, vRIC shows that SARS-CoV-2 RNA engages with a broad 5 
range of cellular RBPs, including classical and unconventional RNA binders.  6 
Viral proteins that interact with viral and cellula r RNA 7 
Both cRIC and vRIC agree in the behaviour of SARS-CoV-2 proteins that interact with 8 
RNA, even though these methods employ different crosslinking chemistries (Castello et 9 
al., 2012). Viral RBPs include the polyprotein ORF1a/b, NCAP, and, surprisingly, M, S 10 
and ORF9b (Figure 1E-F, 5E, 6A-B and S6A). To determine which type of interaction 11 
these proteins establish with RNA, we normalised the protein intensity in vRIC and cRIC 12 
by that of the WCP (Figure 6A-B, S6A and Table S6). NCAP and ORF1a/b displayed the 13 
highest UV ‘crosslink-ability’, followed by M, ORF9b and S. Generally, the efficiency of 14 
crosslinking depends on several factors, including 1) the geometry of the protein-RNA 15 
interaction (contacts with the nucleotide bases), 2) the physicochemical properties of the 16 
bases and amino acids in close proximity, 3) the duration of the interaction, and 4) the 17 
proportion of the protein that engages in RNA binding. We can thus suggest that 18 
ORF1a/b and NCAP establish optimal and stable interactions with RNA, while M, 19 
ORF9b and, especially, S mediate shorter-lived and/or geometrically less favourable 20 
interactions for crosslinking. However, the high protein sequence coverage and peptide 21 
intensity in both vRIC and cRIC experiments strongly support that all these proteins 22 
interact with viral RNA (Figure 6C-E and S6B).  23 
ORF1a/b is a polyprotein comprising of 16 mature polypeptides. While the peptides 24 
detected in the WCP mapped uniformly throughout the polyprotein, both cRIC and vRIC 25 
identified peptides clustered only in specific regions (Figure 6C). The first peptide cluster 26 
mapped to NSP1 and was only detected by cRIC (both 8 and 24 hpi). The lack of signal 27 
in vRIC samples strongly indicates that NSP1 does not interact with viral RNA but 28 
cellular mRNAs, which are highly enriched by the oligo(dT) (Figure S2F). Similarly, the 29 
SARS-CoV-2 RNA interactome from (Schmidt et al., 2020) detected NSP1 with a single 30 
peptide with close-to-noise intensity levels, and (Tidu et al., 2020) did not detect 31 












appears to promote selective translation of viral RNAs, this regulatory effect seems not 1 
to involve a direct interaction with them. The second peptide cluster mapped to NSP9 2 
and is present in both vRIC and cRIC (Figure 6C). The detection of NSP9 by vRIC 3 
agrees well with its known role in viral replication and the well-established interaction of 4 
its SARS-CoV-1 orthologue with single stranded RNA (Chandel et al., 2020; Egloff et al., 5 
2004). The third peptide cluster mapped to the RNA helicase NSP13, which is critical for 6 
SARS-CoV-2 replication (Chen et al., 2020). Cluster 3 peptides are only detected by 7 
vRIC, which supports that NSP13 only interacts with viral RNA.  8 
The proteins M and S also reliably and robustly co-purify with RNA upon cRIC and vRIC 9 
(Figure 1E-F, 5E, 6A-B, E and S6B). The most likely scenario in which these proteins 10 
could engage with viral RNA is during virus assembly and within viral particles (Klein et 11 
al., 2020; Yao et al., 2020). To determine if M and S have sequences compatible with 12 
RNA binding, we used RBDetect, a software package that predicts RBDs based on 13 
amino acid sequence. Strikingly, we detected two segments in the intravirion region of M 14 
that share sequence similarities with bona fide RNA-binding sites present in cellular 15 
RBPs (Figure S6C). Similarly, the intravirion part of S also harbours a ~15 amino acid 16 
motif compatible with RNA binding (Figure S6C). Both M and S RNA-binding regions are 17 
present in both SARS-CoV-2 and SARS-CoV-1, suggesting that the underlying functions 18 
are conserved. While we cannot fully rule out that these interactions with RNA are 19 
stochastic due to protein-RNA proximity in the context of the virion, their prominence in 20 
the vRIC and cRIC data suggest that they may play a role in infection (Figure 6C-E and 21 
S6B). For example, they may contribute to the recruitment of viral RNA, or to the 22 
budding and/or structural arrangement of the viral particle. Importantly, NCAP clusters 23 
locate underneath the viral envelope during budding of the viral particles, and this 24 
structure persists in the mature particles (Klein et al., 2020; Yao et al., 2020). Cryo-25 
electron tomography analysis of infected cells revealed that membrane invagination at 26 
the budding site appears to require the presence of NCAP (Klein et al., 2020), implying a 27 
potential role for RNA in the process of particle formation. 28 
The viral protein ORF9b was also consistently identified by both cRIC and vRIC, 29 
supporting that it is a novel RNA-binding protein (Figure 1E-F, 5E and 6A-B). Very little 30 
is known about ORF9b beyond its ability to interfere with interferon responses (Jiang et 31 












we used RBDetect (sequence-based software) and, given the availability of a deposited 1 
structure (6Z4U) (Weeks et al., In preparation), we also considered  surface 2 
physicochemical properties (BindUP) (Paz et al., 2016). Both approaches agree that 3 
there is a discrete region in ORF9b that generates a positively charged surface with high 4 
probability to interact with nucleic acids (Figure 6G and S6C and D). Further work is 5 
required to define the role of the RNA-binding activity of ORF9b in SARS-CoV-2 6 
infection. 7 
Therefore, our data reveal seven viral proteins that harbour RNA-binding activity, six of 8 
which interact with SARS-CoV-2 RNA. Amongst these, M, S, ORF9b emerge as novel 9 
RBPs based on both our study and (Schmidt et al., 2020).  10 
Functional importance of cellular RBPs in SARS-CoV- 2 infection 11 
To determine if our study has potential for discovery of new regulators of SARS-CoV-2 12 
infection, we assessed the incidence of vRIC and cRIC identified proteins in genome 13 
wide screens with other viruses. The superset includes studies using RNA interference 14 
(RNAi), CRISPR-Cas9, and haploid line screens for 36 viruses (Table S7). This analysis 15 
revealed that cRIC and vRIC identified 47 RBPs linked to phenotypes in functional 16 
screenings (>3 studies; Figure 7A, B, S7A, Table S7).  Moreover, we used an automated 17 
PubMed search pipeline to assess how many RBPs have been robustly linked to virus 18 
infection in the literature. Interestingly, 73 (43.5%) of the RBP upregulated in cRIC, 51 19 
(32.5%) of the downregulated in cRIC and 67 (51.1%) of the RBPs detected by vRIC 20 
were already linked to virus infection (Figure S7B). These results indicate that our 21 
dataset is rich in regulators of viral infection.  22 
To determine the biomedical potential of cellular RBPs for COVID-19 treatment, we 23 
compared the subset of RBPs stimulated by SARS-CoV-2 infection and the subset of 24 
proteins that interact with SARS-CoV-2 RNA to drug databases (Figure S7C). 25 
Importantly, 54 proteins within these datasets have potential inhibitors available (Figure 26 
S7C). To prove the value of these RBPs as therapeutic targets, we tested five drugs in 27 
Calu-3 cells infected with SARS-CoV-2 (Figure 7C and S7D). Our results show that two 28 
of these compounds targeting HSP90 and IGF2BP1 (IMP1) cause a strong inhibition of 29 
SARS-CoV-2 protein production, with two additional drugs targeting ELAVL1 (HuR) and 30 












The anti-SARS-CoV-2 effects of HSP90 inhibitors have been recently confirmed by an 1 
independent study (Wyler et al., 2021).  These results reflect the potential of RBPs as 2 
targets for antiviral drugs. 3 
The tRNA ligase complex, a new regulator of SARS-Co V-2 infection 4 
vRIC revealed DDX1, RTCB and FAM98A as components of the SARS-CoV-2 vRNP. 5 
These proteins, together with FAM98B, C14ORF166 (CGI99, CLE) and C2ORF49 6 
(ASW) form the tRNA ligase complex (tRNA-LC) (Popow et al., 2011). DDX1, RTCB, 7 
FAM98A and FAM98B interact directly with RNA and are regulated by both SARS-CoV-8 
2 and SINV infection. While DDX1 displayed a continuous increase in RNA-binding 9 
activity in the cRIC experiment, the other proteins follow an early inhibition and late 10 
increase pattern (Figure 7D). The tRNA-LC mediates the ligation of unusual RNA 11 
fragments, one with 3´-phosphate or 2’, 3´-cyclic phosphate, and the other a 5´-hydroxyl 12 
group (Popow et al., 2011; Popow et al., 2014). Only few endonucleases can cleave 13 
RNA in this way, including the endoplasmic reticulum resident protein IRE1, which is 14 
activated in response to unfolded protein response (UPR) (Jurkin et al., 2014; Popow et 15 
al., 2011). Viruses are known to cause UPR, suggesting that they should activate the 16 
endonuclease IRE1 (Galluzzi et al., 2017). UPR leads to the tRNA-LC-dependent, 17 
cytoplasmic splicing of Xbp1 mRNA, which encodes a critical transcription factor that 18 
coordinates the cellular responses to UPR (Jurkin et al., 2014).  19 
The regulation of the RNA-binding components of the tRNA-LC by SARS-CoV-2 20 
infection and their presence in viral RNPs suggest their involvement in the viral lifecycle. 21 
To confirm the interaction between the tRNA-LC and SARS-CoV-2 RNA, we performed 22 
an immunofluorescence analysis of infected Calu-3 cells. DDX1, a core component of 23 
the tRNA-LC, concentrates at the cytoplasmic foci where dsRNA accumulates, 24 
confirming that DDX1 engages with SARS-CoV-2 RNA.  25 
To test the relevance of the tRNA-LC in SARS-CoV-2 infection, we generated A549-26 
ACE2 cells with tetracycline inducible expression of shRNAs against DDX1 and 27 
FAM98A. Knocking down of DDX1 led to the depletion of other components of the tRNA-28 
LC, including the ligase RTCB, FAM98A and, to a lesser, extent CIG-99 (Figure 7F and 29 
S7E). These results support previous observations showing that the stability of the 30 











Knock down of the peripheral member of the tRNA-LC, FAM98A, causes minor effects in 1 
the levels of the other components (Figure S7E). Importantly, silencing of DDX1 caused 2 
a strong reduction of intracellular SARS-CoV-2 RNA that correlates with a parallel 3 
reduction of NCAP (Figure 7E-F and S7E). FAM98A KD led to milder effects in both viral 4 
RNA levels and NCAP accumulation (Figure 7F-G and S7E). Since DDX1 is a core 5 
subunit of the tRNA-LC and FAM98A is secondary, these differential effects are 6 
expected. To provide further insights into the effects of DDX1 KD, we generated 7 
RNAseq data. We observed that DDX1 KD equally affected all viral transcripts, despite 8 
having no effect on cell viability (Figure 7H). Conversely, DDX1 KD had no detectable 9 
effects in xbp1 mRNA expression and splicing and, with few exceptions, most UPR 10 
response genes remained unaltered (Figure 7H and S7G-J). This indicates that either 11 
DDX1 KD leaves sufficient tRNA-LC for the xbp1 mRNA splicing to occur or, 12 
alternatively, that SARS-CoV-2 does not produce a strong UPR response in A549-ACE2 13 
cells. These results suggest that tRNA-LC plays a role in SARS-CoV-2 replication. 14 
OUTLOOK  15 
We provide a systematic and comprehensive analysis of protein-RNA interactions in 16 
SARS-CoV-2 infected cells. We show that SARS-CoV-2 infection induces a pervasive 17 
remodelling of the RBPome which involves the upregulation and downregulation of more 18 
than three hundred RBPs. We also discovered dozens of cellular proteins that interact 19 
with SARS-CoV-2 RNAs, which are promising for the development of new therapeutic 20 
approaches. Importantly, we find shared host-virus interactions between the viruses 21 
SARS-CoV-2 and SINV, which reflect the existence of cellular RBPs with ‘master’ 22 
regulatory roles in virus infection. Similar work with other viruses and cell types will 23 
expand our knowledge on these critical protein-RNA interactions. The relevance and 24 
complementarity of our datasets is illustrated by the discovery of the tRNA-LC as a key 25 
regulator of SARS-CoV-2 as well as RBP-targeting compounds with antiviral activity. 26 
Our study also discovers novel viral RNPs, including S, M and ORF9b, opening new 27 
angles to investigate their roles in SARS-CoV-2 infection. 28 
In the future, cRIC and vRIC could be extended to other coronaviruses and other 29 
biological models such as primary cells and organoids. Generating additional time points 30 
and using replication inhibitors such as Remdesivir, it will be possible to study the 31 












with CLIP-based methods will make it possible to identify the motifs that cellular RBPs 1 
recognise in viral RNAs and will provide new insights into their function in infection. We 2 
are hopeful that this work will further shed light on the pathogenesis of SARS-CoV-2 and 3 
accelerate the discovery of therapies for COVID 19. 4 
Limitations of the study 5 
As any proteomic approach, RIC and vRIC have a bias related to protein abundance, 6 
size, and physicochemical properties of their tryptic peptide sequences. UV irradiation 7 
induces RNA-to-protein crosslinks in a very specific manner as it requires zero 8 
‘distances’. However, the higher specificity comes at a price of lower efficiency when 9 
compared to chemical crosslinkers such as formaldehyde. UV underperforms with 10 
transitory interactions and contacts with the ribose-phosphate backbone as the 11 
crosslinking is mediated by the nucleotide base (Castello et al., 2016). These biases 12 
may explain why several proteins within ORF1a/b that have been linked to viral RNA 13 
metabolism are not identified by vRIC. In the case of vRIC, the combination of 4SU and 14 
fvo could potentially have undesired effects, and we recommend titrating both 15 
compounds to avoid/minimise side effects in cell viability and virus fitness (Figure S5A-16 
D). Here, we combined vRIC with oligo(dT) capture; however, it is compatible with 17 
virtually any RNA isolation approach, including specific antisense probes or total RNA 18 
isolation approaches. These alternatives must be evaluated when working with non-19 
polyadenylated viruses. 20 
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FIGURE LEGENDS 16 
Figure 1. RBPome analysis in SARS-CoV-2 infected ce lls.  A) Schematic 17 
representation of cRIC. B) Proportion of infected cells estimated by immunofluorescence 18 
using an antibody against dsRNA. C) RT-qPCR analysis of SARS-CoV-2 RNA in cells 19 
and in the supernatant of infected cells. D) Number of adhered cells at different times 20 
post SARS-CoV-2 infection counted using DAPI stain. Error bars in B, C and D 21 
represent the standard error of the mean (SEM); n=3. E) Proportion of the RBPs that are 22 
annotated by the GO term ‘RNA-binding’. F) Proportion of RBPs that harbour known 23 
RBDs. G) Volcano plots showing the log2 fold change (x axis) and its significance (adj. 24 
p-value, y axis) of each protein (dots) in the cRIC experiments (n=3). 1% FDR proteins 25 
are in blue and red, 10% FDR proteins in orange and cyan. 26 
Figure 2. Factors influencing RBP remodelling in SA RS-CoV-2 infected cells.  A) 27 
Proteomic analysis of the whole cell proteome (inputs) of the cRIC experiment. Volcano 28 
plots showing the log2 fold change and adjusted p-value of each protein (n=3). 1% FDR 29 












showing the fold changes in cRIC and those in the WCP. In red and blue are the RBPs 1 
upregulated or downregulated in the cRIC experiment (FDR<10%). C) MA plot 2 
highlighting significant changes in gene expression in SARS-CoV-2 infected Calu-3 cells 3 
as detected by RNA sequencing. D) Fraction of uniquely aligned RNA-seq reads 4 
mapping to human chromosomes or SARS-CoV-2 genome in uninfected and infected 5 
cells. E) Bar plot showing the odds ratio of previously reported total and SARS-CoV-2 6 
differentially regulated posttranslational modifications (PTMs) in upregulated and 7 
downregulated RBPs, relative to the non-regulated RBPs within the cRIC experiment. *, 8 
p<0.1; **, p<0.05; ***, p<0.01. 9 
Figure 3. Clustering of RBP responses to SARS-CoV-2  infection.  A) Cluster analysis 10 
of the RBP dynamics using data from uninfected cells, 8 hpi and 24 hpi. B) Protein-11 
protein interaction network of the translation initiation complex and the exon junction 12 
complex generated with STRING. Proteins are coloured based on the cluster in panel A.   13 
Figure 4. Analysis of RBP dynamics in SARS-CoV-2 an d SINV infected cells.  A) 14 
Scatter plot of the fold change between infected and uninfected cells, using the data 15 
from the cRIC experiments in SARS-CoV-2 (24 hpi) and SINV (18hpi) infected cells. 16 
Proteins were grouped based on their behaviour (B) and the overlap between datasets 17 
was estimated (C). D) Fold change of selected proteins in SARS-CoV-2 (red) and SINV 18 
(blue) cRIC analyses. ‘Early’ and ‘Late’ are 8 and 24 hpi for SARS-CoV-2 and 4 and 24 19 
hpi for SINV. * FDR < 20% ; ** FDR < 10% and *** FDR < 1%. 20 
Figure 5. vRIC analysis of the SARS-CoV-2 RNA inter actome.  A) Schematic 21 
representation of vRIC. B) Controls used in the vRIC experiment (expanded in Figure 22 
S5E). C) Effects of 4SU and Fvo on SARS-CoV-2 RNA levels analysed by RT-qPCR. D) 23 
Principal component analysis (PCA) of vRIC in SARS-CoV-2 infected and uninfected 24 
cells (n=4). E)  Volcano plots showing the log2 fold change and adj. p-value of each 25 
protein in the vRIC experiment. 1% FDR proteins are shown in red and 10% FDR 26 
proteins are in orange. F-G) Proportion of the proteins enriched by vRIC that are 27 
annotated by the GO term ‘RNA-binding’ (F) or harbour classical RBDs (G). H) GO 28 
enrichment analysis of the proteins enriched by vRIC. I) Proportion of the proteins 29 
enriched by vRIC that are annotated to immunity in GO or KEGG. J)  Scatter plot 30 












from SARS-CoV-2 and SINV-infected cells. On the right, box plot showing the 1 
overlapping between the two datasets.   2 
Figure 6. SARS-CoV-2 proteins that interact with RN A. A and B) Representative 3 
scatter plot showing the cRIC (left, 24 hpi/mock)) or vRIC (right, infected/uninfected) fold 4 
change normalised to the fold change in the WCP (24 hpi/mock). Replicates 1 and 2 5 
were chosen as illustrative examples and the rest of comparisons can be found in Figure 6 
S6A. Cellular RBPs upregulated in the cRIC experiments (Figure 1G) are coloured in 7 
yellow, cellular RBPs enriched in SARS-CoV-2 vRIC (Figure 5E) are shown in violet, 8 
and viral proteins in red. C and D) Sequence coverage analysis. Peptides detected in 9 
WCP (blue), cRIC (green) and vRIC (violet) are mapped to the viral proteins plotted from 10 
N-terminus to C-terminus (x axis). E) Boxplot showing peptide intensity distribution in 11 
cRIC, vRIC and WCP for each of the viral proteins detected. Colours as in C-D. G) 12 
ORF9b structure showing the protein surface (PDB ID: 6z4u). Peptides with high 13 
probability of RNA binding by RBDetect (left) or BindUP (right) are coloured in blue. 14 
Figure 7. Functional characterisation of protein-RN A interactions in SARS-CoV-2 15 
infected cells.  A-B) Proteins with identified phenotypes in genome-wide screens using 16 
viruses. RBPs enriched in SARS-CoV-2 vRIC (A) or upregulated in the cRIC experiment 17 
(B) are displayed along the x axis, while y axis indicates the number of screens in which 18 
the protein has caused a phenotype in infection. C) Effects of RBP inhibitors on SARS-19 
Cov-2 infection. Red line indicates the effects in infection measured by protein ELISA at 20 
each drug dose. Black line shows cell viability at each drug dose. Error bars are SEM 21 
from three independent experiments. D) RNA binding profiles of the components of the 22 
tRNA ligase complex in SARS-CoV-2 (red) and SINV (blue) infected cells (As in Figure 23 
4D) *, FDR < 20% ; **, FDR < 10% and *** FDR < 1%. E) Confocal immunofluorescence 24 
images of SARS-CoV-2 and mock-infected Calu-3 cells using antibodies against DDX1 25 
and dsRNA. Fluorescence plot shows green and red fluorescence intensity profiles 26 
across an 8 µm section (white line). F) Western blot analysis showing the nucleocapsid 27 
(NCAP), components of the TLRC complex and β-actin (ACTB) levels in control cells 28 
and upon DDX1 or FAM98A knock down. G) SARS-Cov-2 RNA levels in control cells 29 
and upon DDX1 or FAM98A knock down measured by RT-qPCR and normalised to β-30 
actin mRNA. Error bars are SEM from three independent experiments. H) RNAseq 31 












Data is represented in a box plot, showing different mRNA groups (all, SARS-CoV-2, 1 
tRNA-LC and UPR genes). Significant changes (p<0.05) are shown in red and blue.   2 












STAR methods 1 
Resource availability 2 
Lead contact 3 
Further information and requests for resources and reagents should be directed to and 4 
will be fulfilled by the Lead Contact, Alfredo Castello (alfredo.castello@glasgow.ac.uk). 5 
Material availability 6 
Material is available upon request from the authors. 7 
Data and code availability 8 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 9 
Consortium via the PRIDE partner repository with the dataset identifier PXD023418. The 10 
accession number for the RNA sequencing data reported in this study is GEO: 11 
GSE171382. Additional Supplemental Items are available from Mendeley Data at 12 
http://dx.doi.org/10.17632/fcvjnp9mff.1.  13 
Experimental model and subject detail   14 
Cell culture   15 
Calu-3 cells (kind gift from Dr. Manfred Frey, Mannheim, Germany) were maintained in 16 
DMEM (Gibco, 41965039) with 20% fetal bovine serum (FBS) (Gibco, 10500064) and 1x 17 
penicillin/streptomycin (Sigma Aldrich, P4458) at 37°C with 5% CO2. A549-Ace2 (Klein 18 
et al., 2020) were maintained as above with 10% FBS. Both cell lines are male. To 19 
generate inducible knockdown lines, cells were infected with Lentiviral vectors derived 20 
from pLKO-Tet-On (Wiederschain et al., 2009) with the guide sequence 21 
GATGTGGTCTGAAGCTATTAA for DDX1 and GCACATTCAGTAGCCTTATTT for 22 
FAM98A. Lentiviruses were produced by co-transfection of HEK293T cells with pHEF-23 
VSVG (NIH AIDS Research & Reference reagent program #4693) and psPAX2 (kind gift 24 
N. Proudfoot, Oxford, UK). After infection of A549-Ace2 cells with the lentiviruses, 25 












Viruses   1 
Infection of Calu-3 cells for virus growth kinetics, cRIC, vRIC, WCP and drug screen was 2 
performed using isolate hCoV-19/Germany/BavPat1/2020 (European Virology Archives: 3 
026V-03883, EPI_ISL_406862). For validation in knockdown studies and 4 
immunofluorescence, hCoV-19/England/02/2020 (Public Health England propagated 5 
viral isolate Feb 2020, EPI_ISL_407073) was used.  6 
Method details 7 
Virus growth kinetic experiments  8 
1.2 x 105 Calu-3 cells were seeded into each well of a 24-well plate. Cells were infected 9 
24 hours after seeding with SARS-CoV-2 at a multiplicity of infection (MOI) of 1. To 10 
determine infectivity, 50 µl of supernatant from each well was used in plaque assays. 11 
Plaque assays were performed as previously described (Klein et al., 2020). Briefly, 2.5 x 12 
105 Vero cells were seeded into each well of a 24-well plate and cells were inoculated 13 
with 10-fold serial dilutions of SARS-CoV-2 containing supernatants for 1 h at 37°C. 14 
After 1h, viral supernatants were replaced by serum-free MEM (Gibco #11095080, Life 15 
Technologies) containing 0.8% carboxymethylcellulose (Sigma, 11095080). Three days 16 
later, plates were fixed with 6 % formaldehyde for 30 minutes and rinsed with tap water. 17 
Plates were stained with a solution containing 1% crystal violet (Sigma, HT90132-1L) 18 
and 10% ethanol for 30 min. After rinsing with tap water, plaques were counted to 19 
determine viral titer. 20 
For intra- and extra-cellular RNA extraction, NucleoSpin RNA extraction kit (Macherey-21 
Nagel, #740955.50) was used following the manufacturer’s specifications. cDNA 22 
synthesis from the total RNA isolated was achieved using a high-capacity reverse 23 
transcription kit (ThermoFisher, #4368814). cDNA samples were diluted 1:15 and used 24 
for qPCR with the iTaq Universal SYBR green mastermix (Biorad, #1725120). Cycle 25 
threshold values were corrected for PCR efficiency of each primer set and normalized to 26 
the hypoxanthine phosphoribosyltransferase 1 (HPRT) mRNA to determine relative 27 
abundance of viral RNA for each sample (see table S8). 28 












To establish cell viability and infection rate, 1.2 x 105 Calu-3 cells were seeded into each 1 
well of a 24-well plate onto glass coverslips. Mock-infected and SARS-CoV-2-infected 2 
cells were fixed at the times post infection indicated in the figures with 6% formaldehyde 3 
for 30 min. Cells were washed twice with PBS (phosphate-buffered saline) and 4 
permeabilized with 0.2% Triton X-100 in PBS. Permeabilized samples were incubated 5 
with blocking solution (2% of milk and 0.02% Tween-20 in PBS) for 1 h at room 6 
temperature. Samples were stained with primary antibodies specific to dsRNA (see 7 
Table S8) as well as DAPI (DAPI Fluoromount-G, SouthernBiotech, 0100-20) to 8 
visualize the nuclei using a Nikon Eclipse Ti microscope (Nikon, Tokio, Japan). Three 9 
replicates per time point were analyzed. Nuclei were counted with a custom-made 10 
macro for the Fiji software package (Schindelin et al., 2012). Number of nuclei in 11 
infected samples were normalized to the non-infected control counterparts. To 12 
determine the infection rate, the number of infected cells at each time point was 13 
determined using the dsRNA fluorescence signal with Fiji software using a custom 14 
macro (Schindelin et al., 2012). 15 
Cell viability assay of knockdown cell lines 16 
A549-Ace2 cells and the derived shRNA cell lines were cultured in doxycycline 17 
containing media (1 µg/ml) to induce shRNA expression for >14 days. 5x104 cells per 18 
condition were transferred into a 96-well plate. 24 hours later, ATP levels were 19 
measured using CellTiter-Glo 2.0 (Promega #G9241) on a BMG CLARIOStar Plus. 20 
 21 
Colorimetric cell-based assay to assess the effects  of RBP inhibitors in SARS-22 
CoV-2 infection 23 
Calu-3 cells were seeded at 2 x 104 cells per well of 96-well plate. Cells were treated 24 24 
hours later with 2-fold serial dilutions of the indicated compounds in duplicate wells. 25 
Dilutions ranged from 2.5 nM to 50 µM for Ro 08-2750 (TOCRIS, #2272) and the 26 
BTYNB IMP1 inhibitor (Cayman Chemical, #25623), 5 nM to 100 µM for Ganetespib 27 
(BIOZOL, BYT-ORB181166) and MS-444 (Hycultec, HY100685-1mg) and 1,25 nM to 25 28 
µM for the PKM2 inhibitor - compound 3k (BIOZOL, SEL-S8616)). 2 hours after 29 
treatment, cells were infected with SARS-CoV-2 (BavPat1/2020 strain) at a MOI of 2. At 30 












washed twice with PBS (Phosphate-buffered Saline) and permeabilized with 0.2% Triton 1 
X-100 in PBS. Permeabilized samples were then incubated with blocking solution (2% of 2 
milk and 0.02% Tween-20 in PBS) for 1 h at room temperature. Blocking solution was 3 
replaced with primary antibodies specific for SARS-CoV NCAP (Table S8) diluted in 4 
blocking solution. Cells were incubated for 1 h at 37 °C, washed four times with PBS 5 
followed by incubation with horse radish peroxidase (HRP)-conjugated secondary 6 
antibodies diluted in PBS (containing 0.02% Tween-20) for 1 h at 37 °C. Wells were 7 
washed 3 times with PBS. PBS excess was carefully removed, and wells were 8 
developed by adding 50 µl of TMB Microwell Peroxidase (SeraCare, Cat: 5120-0077) to 9 
each well for 5 min followed by 50 µl of 0.5 M of H2SO4 solution to stop the reaction. 10 
Absorbance was measured at 450 nm using a Tecan-Sunrise absorbance microplate 11 
reader. Values were normalized to vehicle (DMSO). In order to assess the effects of the 12 
above-mentioned inhibitors on cell viability, we employed the commercial kit 13 
CellTiterGlo® Luminescent Cell Viability Assay (Promega, Cat: G7570) on a Mithras LB 14 
940 plate reader (Berthold Technologies). The assays were performed following the 15 
manufacturer’s instructions in uninfected cells for the different doses of each 16 
compounds. Luminiscence values were normalised to vehicle (DMSO).  17 
Immunofluorescence   18 
Round #1.5 (diameter 13 mm) coverslips (Thermo Fischer Scientific) were wiped with 19 
lint-free tissue soaked in 80% ethanol and washed in 100% ethanol twice for 2 h. 2x105 20 
Calu-3 cells were seeded on the dried coverslips and incubated in growth media for 48 21 
hours prior to the experiment. Cells were infected with 2x105 PFU/well (MOI=1) SARS-22 
CoV-2 (hCoV-19/England/02/2020) and incubated for 24 hours. Cells were fixed in 4% 23 
formaldehyde for 30 minutes and washed once with PBS. Cells were permeabilised for 24 
10 min with PBSTx (1x PBS + 0.1% Triton X-100) at room temperature. Next, cells were 25 
washed twice in PBSTw (1x PBS + 0.1% Tween-20) for 5 min each and incubated in 26 
blocking solution (PBSTw + 2.5% goat serum + 2.5% donkey serum) for 1 h at room 27 
temperature. Cells were incubated overnight at 4˚C with primary antibodies diluted in 28 
blocking solution (table S8). Coverslips were then washed three times with PBSTw for 29 
10 min each at room temperature and incubated with secondary antibodies and DAPI (1 30 
µg/ml) diluted in blocking solution overnight at 4˚C. Cells were washed three times with 31 












were mounted on glass slides using Vectashield HardSet mounting medium (Vector 1 
Laboratories #H-1400). Mounted cells were imaged on an Olympus SoRa spinning disc 2 
confocal with Orca Flash4 CMOS camera using 100x silicone oil objective (1.35 NA, 3 
UPLSAPO100XS). Specimens were imaged in at least six different locations per 4 
coverslip. 3D-stacked images were taken with voxel size of 80 nm x 80 nm x 200 nm in 5 
x:y:z and images were deconvolved with maximum likelihood algorithm using cellSens 6 
(5 iterations, default PSF, no noise reduction, Olympus). Background subtraction was 7 
performed on all channels using rolling ball subtraction method (radius = 250 px) in 8 
ImageJ (National Institutes of Health). Fluorescence intensity profiles were obtained 9 
using ImageJ “Plot profile” tool across 8 µm regions on 0.4 µm max intensity z-projected 10 
images. Voxel intensities were normalized to maximum intensity value obtained from 11 
‘SARS-CoV-2 infected’ condition. 12 
qRT-PCR and RNA sequencing of knockdown lines 13 
To induce shRNA expression A549-Ace2 cells and the derived shRNA lines were 14 
cultured in doxycycline containing media (1 µg/ml) for >14 days. 2.5x105 cells each were 15 
seeded into a 24-well plate and Cells were infected with 2x104 PFU/well (MOI=0.1) of 16 
SARS-CoV-2 (hCoV-19/England/02/2020). At 24 hpi, cells were detached and lysed in 17 
Trizol LS. Total RNA extraction was performed following manufacturers 18 
recommendation. qRT-PCR was performed using Luna (NEB # E3005L) with gene 19 
specific primers (table 8). RNA sequencing libraries were prepared using the Illumina 20 
Total RNA Prep with Ribo-Zero Plus library kit (Cat# 20040525) according to 21 
manufacturer’s guidelines. Briefly, 100ng of total RNA was first depleted of the abundant 22 
ribosomal RNA present in the samples by rRNA targeted DNA probe capture followed by 23 
enzymatic digestion. Samples were then purified by Beckman Coulter RNAClean XP 24 
beads (Cat #A63987). Obtained rRNA-depleted RNA was fragmented, reverse 25 
transcribed, converted to dsDNA, end repaired and A-tailed. The A-tailed DNA 26 
fragments were ligated to anchors allowing for PCR amplification with Illumina dual 27 
indexing primers (Cat#20040553). Libraries were pooled in equimolar concentrations 28 
and sequenced on an Illumina NextSeq 500 sequencer using a high-output cartridge 29 
(Cat# 20024907), generating single 150bp long reads. 30 
 31 












Comparative RNA interactome capture (cRIC) was performed based on the previously 1 
described protocol (Castello et al., 2013; Perez-Perri et al., 2020a)  with the following 2 
alterations: Calu-3 cells were grown in sets of 3x15 cm dishes with 107 cells/dish. One 3 
set of dishes remained uninfected while a second set was infected with SARS-CoV2 4 
(hCoV-19/Germany/BavPat1/2020) at a MOI of 1. One of these infected cell sets was 5 
incubated for 8 h and the other for 24 h. 3 biological replicates for each condition were 6 
performed. After incubation, plates without lids were placed on ice and cells were 7 
irradiated with 150 mJ/cm2 of UV light at 254 nm and lysed with 5 mL of lysis buffer (20 8 
mM Tris-HCl pH 7.5, 500 mM LiCl, 0.5% LiDS wt/vol, 1 mM EDTA, 0.1% IGEPAL (NP-9 
40) and 5 mM DTT). Lysates were homogenized by passing the lysate at high speed 10 
through a 5 mL syringe with a 27G needle, repeating this process until the lysate was 11 
fully homogeneous. Ten percent of the lysate was separated for total proteome analysis 12 
(WCP). The rest of the samples were processed as follows. Protein content was 13 
measured using Qubit protein assay (Invitrogen Q33212) and lysates were normalized 14 
by protein content. 0.45 mL of pre-equilibrated oligo(dT)25 magnetic beads (New 15 
England Biolabs, #S1419S) were added to the lysates and incubated for 1 h at 4°C with 16 
gentle rotation. Beads were collected in the magnet and the lysate was transferred to a 17 
new tube and stored at 4°C. Beads were washed once with 5 mL of lysis buffer, followed 18 
by two washes with 5 mL of buffer 1 (20 mM Tris-HCl pH 7.5, 500 mM LiCl, 0.1% LiDS 19 
wt/vol, 1 mM EDTA, 0.1% IGEPAL and 5 mM DTT), and two washes with buffer 2 (20 20 
mM Tris-HCl pH 7.5, 500 mM LiCl, 1 mM EDTA, 0.01% IGEPAL and 5 mM DTT), in all 21 
cases incubating the beads for 5 min at 4°C with gentle rotation. Beads were then 22 
washed twice with 5 mL of buffer 3 (20 mM Tris-HCl pH 7.5, 200 mM LiCl, 1 mM EDTA 23 
and 5 mM DTT) at room temperature for 3 minutes. Beads were resuspended in 300 µL 24 
of elution buffer and incubated for 3 min at 55°C with agitation. After collecting the beads 25 
with a magnet, eluates (supernatants) were collected and stored at −80°C. The lysates 26 
were subjected to a second round of capture and the eluates from the first and second 27 
cycles were combined. Prior to mass spectrometry sample processing, samples were 28 
RNase treated with ~0.02U RNase A and RNase T1 at 37°C for 1h. 29 
Viral RNA interactome capture  30 
Viral RNA interactome capture was performed as in (Kamel et al., In preparation). 31 












(SARS-CoV2/4SU/Fvo), at 8hpi (hours post-infection, MOI=1), the growth media were 1 
replaced with fresh media supplemented with (20 µM Flavopiridol hydrochloride hydrate 2 
(Fvo, Cat.No. F3055, Sigma-Aldrich)) and 100 µM 4-Thiouridine (4SU, Cat.No. T4509, 3 
Sigma-Aldrich)). The plates were returned to the incubator for additional 16 hours. At 4 
24hpi, growth media were discarded, and the cells were rinsed once with PBS 5 
(Phosphate-buffered saline). Cells were irradiated twice with at 200 mJ/cm2 using 6 
ultraviolet light 365nm. At this stage, samples were subjected to the standard RNA-7 
interactome capture described above. For the control uninfected samples (M/4SU/Fvo), 8 
cells were treated as in SARS-CoV-2/4SU/Fvo with exception of not adding the virus. 9 
Both M/4SU/Fvo and SARS-CoV-2/4SU/Fvo were performed in sets of four biological 10 
replicates. Additional controls, (M/4SU/-), uninfected cells were treated as in M/4SU/Fvo, 11 
without the addition of Fvo, and (M/-/-) uninfected cells were incubated with growth 12 
media (not supplemented with Fvo and 4SU) and not crosslinked. Both (M/4SU/-) and 13 
(M/-/-) were performed in sets of three biological replicates. 14 
Mass spectrometry   15 
Prior to MS sample preparation, WCP samples were treated with benzonase for 30 min 16 
at room temperature to degrade both RNA and DNA. The cRIC, vRIC and WCP protein 17 
samples were processed via the bead-based single-pot, solid-phase-enhanced sample-18 
preparation (SP3) method, using Speed Bead Magnetic Carboxylate Modified Particles 19 
(Sigma-Aldrich, cat.no.45152105050250) (Hughes et al., 2019). Protein digestion was 20 
performed using Trypsin Gold (MS grade; Promega, cat. no. V5280). Processed 21 
peptides were acidified by formic acid (final concentration 5%) prior to Mass 22 
spectrometry analysis.  23 
For cRIC and vRIC peptides, liquid chromatography (LC) was preformed using Ultimate 24 
3000 ultra-HPLC system (Thermo Fisher Scientific). Peptides were initially trapped in 25 
C18 PepMap100 pre-column (300 µm inner diameter x 5 mm, 100A, Thermo Fisher 26 
Scientific) in Solvent A (Formic acid 0.1% (v/v), Medronic acid 5 µM). Trapped Peptides 27 
were separated on the analytical column (75 µm inner diameter x 50cm packed with 28 
ReproSil-Pur 120 C18-AQ, 1.9 mm, 120 A, Dr. Maisch GmbH) in a 60min 15%–35% 29 
[vol/vol] acetonitrile gradient with constant 200 nL/min flow rate. Eluted peptides were 30 
directly electrosprayed into a QExactive mass spectrometer (Thermo Fisher Scientific). 31 












70000, AGC target 3 x 106, maximum injection time 50 ms) in a data-dependent mode. 1 
the top 10 most abundant peaks were fragmented using CID (resolution 17500, AGC 2 
target 5 x104, maximum injection time 120 ms) with first fixed mass at 180 m/z. 3 
Both WCP and vRIC peptides were analysed using a Dionex Ultimate 3000 RSLC 4 
nanoUPLC (Thermo Fisher Scientific Inc, Waltham, MA, USA) system online with an 5 
Orbitrap Eclipse mass spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA). 6 
Peptides were loaded onto a trap-column (Thermo Scientific PepMap 100 C18, 5 µm 7 
particle size, 100A pore size, 300 µm i.d. x 5mm length) and separation of peptides was 8 
performed by C18 reverse-phase chromatography at a flow rate of 300 nL/min and a 9 
reverse-phase nano Easy-Spray column (Thermo Scientific PepMap C18, 2µm particle 10 
size, 100A pore size, 75µm i.d. x 50cm). WCP peptides were acquired in a 120 min run 11 
while vRIC samples in an 82 min run. Analytical chromatography for WCP peptides 12 
consisted of Buffer A (0.1% formic acid in HPLC-grade water) and Buffer B (80% ACN, 13 
0.1% formic acid). 0-3 min at 2% buffer B, 3-90 min linear gradient 2% to 40% buffer B, 14 
90-90.3 min linear gradient 40% to 90% buffer B, 90.3-95 min at 90% buffer B, 95-95.3 15 
min linear gradient 90% to 2% buffer B and 95.3-120 min at 2% buffer B. Analytical 16 
chromatography for vRIC peptides was Buffer A (HPLC H2O, 0.1% formic acid) and 17 
Buffer B (80% ACN, 0.1% formic acid). 0-3 min at 3.8% buffer B, 3-63 min non-linear 18 
gradient 3.8% to 40% buffer B, 63-63.3 min linear gradient 40% to 90% buffer B, 63.3-68 19 
min at 90% buffer B, 68-68.3 min non-linear gradient 90% to 3.8% buffer B and 68.3-82 20 
min at 3.8% buffer B. All m/z values of eluting peptide ions were measured in an 21 
Orbitrap mass analyzer, set at a resolution of 120 000 and were scanned between m/z 22 
380-1500 Da. Data dependent MS/MS scans (3 second duty cycle time) were employed 23 
to automatically isolate and fragment precursor ions using Collisional-induced 24 
Dissociation (CID) (Normalised Collision Energy of 35%). Only precursors with charge 25 
between 2 to 7 were selected for fragmentation, with an AGC target and maximum 26 
accumulation time of 1×104 and 125 ms respectively. Precursor isolation was performed 27 
by the quadrupole with 1.2 m/z transmission window. MS2 fragments were measured 28 
with the Ion Trap analyser. Dynamic exclusion window was set to 70 seconds. 29 
Protein identification and quantification were performed using Andromeda search engine 30 
implemented in MaxQuant (1.6.3.4) under default parameters (Cox et al., 2011). 31 












(Uniprot_id: UP000005640, downloaded Nov2016) and SARS-CoV-2 (Uniprot_id: 1 
UP000464024, downloaded 24June2020). False discovery rate (FDR) was set at 1% for 2 
both peptide and protein identification. For cRIC and WCP samples, MaxQuant search 3 
was performed with “match between run” activated. For vRIC samples, since each 4 
sample was analyzed on both Eclipse and QExactive mass spectrometers, raw spectra 5 
form both runs were combined as separate fractions in the MaxQuant search (the 6 
spectra from the Eclipse was assigned fraction 1 and the spectra from the QExactive is 7 
assigned fraction 5, and each sample was as independent experiment). 8 
Quantification and statistical analysis 9 
Proteomic quantitative analysis   10 
For relative quantification, MaxQuant outputs (proteinGroups) were used for 11 
downstream analysis. Proteins flagged as potential contaminants were filtered out, using 12 
R-package “DEP (1.4.1)” (Zhang et al., 2018), together with proteins with all missing 13 
values. In case of cRIC and WCP experiments, proteins raw intensities were normalized 14 
and transformed using R-package Variance Stabilizing Normalization “VSN (3.50.0)” 15 
(Huber et al., 2002). Correlation analysis between replicates was preformed using R-16 
package “PerformanceAnalytics (v2.0.4)”. Missing value imputation was only preformed 17 
for proteins with missing values in all replicates in one experimental condition, while 18 
present in the other condition (at least in 2 out of 3 replicates). Imputation was 19 
preformed using local (by sample) minimum determination method (Mindet) (Lazar et al., 20 
2016). Statistical analysis for the processed intensities was performed in R-package 21 
“limma (3.38.3)” (Ritchie et al., 2015) using empirical Bayesian method moderated t-test. 22 
P values were adjusted for multiple-testing using Benjamini-Hochberg method. For the 23 
vRIC experiments, samples were processed as described above with exception of the 24 
normalization step.  25 
Clustering of cRIC responses to SARS-CoV-2 infectio n  26 
Cellular RBP responses to SARS-CoV-2 infection was classified into initial response, 27 
which is defined as cRIC log fold change from mock to early time point post-infection (8 28 
hpi/mock), and progressive response, which is determined by log fold change from early 29 
to late time point post-infection (8 hpi/24 hpi). Protein abundance fold changes in these 30 












RBPs were divided into 8 clusters based on their initial response, progressive response, 1 
and FDR. Clustering was based on an FDR<10% with a log(2) fold change of 0.5 as 2 
thresholds. For clustering of spliceosome/ spliceosome–related proteins, list of different 3 
classes of spliceosomal proteins was obtained from Spliceosomedb (Cvitkovic and 4 
Jurica, 2013). 5 
SARS-CoV-2 proteins RNA binding prediction 6 
RNA binding prediction for regions on the viral protein sequence was performed with 7 
RBDetect. RBDetect is a machine learning model trained by Shrinkage Discriminant 8 
Analysis (SDA) with a dataset of 8891 experimentally identified polypeptides from the 9 
RBDmap experiment, using positive examples (RNA-bound polypeptides) and negative 10 
examples (RNA released polypeptides) (Castello et al., 2016). For each amino acid 11 
position on the viral protein sequence, RBDetect assigns a probability value to bind RNA 12 
based on the fragment centered at that position. Then, a Hidden Markov model is used 13 
to visualize the probabilities in a sequential manner, which helps to determine the most 14 
probable binding regions on a larger scale. 15 
Analysis of the PTM profile of RBPs identified in c RIC 16 
Cellular RBPs detected in cRIC experiments were cross-referenced to phosphorylation 17 
and ubiquitination sites of recent large scale (post-translation modification) PTM 18 
quantification experiments preformed in SARS-CoV-2 infected cells. PTM datasets 19 
obtained from the single-timepoint phospho-proteome work by (Klann et al., 2020), multi-20 
timepoints phospho-proteome work by (Bouhaddou et al., 2020), and multi-level omics 21 
work by (Stukalov et al., 2020). The SARS-CoV-2 regulated RBPome is defined as 22 
RBPs with FDR < 0.1 in the cRIC experiment. SARS-CoV-2 regulated PTM sites are 23 
significant hits in each data sources using the criteria defined in the corresponding 24 
publications. For the multi-timepoint dataset, a PTM site is considered SARS-CoV-2 25 
regulated, if it is determined as significant at any timepoint. Fisher’s exact test was 26 
employed to calculate odds ratios and significance of enrichment of each PTM 27 
annotation in the SARS-CoV-2 upregulated RBPome versus downregulated RBPome. 28 












Cellular RBPs (stimulated upon SARS-CoV-2 infection (from cRIC) or bound to viral 1 
RNA (from vRIC)) were examined for known chemical compound interactions through 2 
the Drug-Gene Interaction database (DGIdb, downloaded Oct-2020) (Cotto et al., 2018).  3 
Gene Ontology (GO) terms  4 
Using the GO annotation available via the GO.db R package (3.11.4), GO terms 5 
including the term 'RNA binding' (to annotate RNA-binding related functions, processes, 6 
or compartments) or term 'immun' or exact terms 'immune response' and 'innate immune 7 
response' (to annotate immunity related functions, processes, or compartments) were 8 
selected. The full list of terms is provided as a supplementary table (Table S9). The R 9 
package org.Hs.eg.db (3.11.4) was used to identify the genes (proteins) in our dataset 10 
that are annotated to these GO terms using the cross-database id mapping functionality. 11 
GO enrichment analysis was performed using PANTHER classification system 12 
(http://www.pantherdb.org) (Mi et al., 2019).  13 
Kyoto Encyclopedia of Genes and Genomes (KEGG) path ways 14 
KEGG pathways under the 'Immune system' category in the high-level KEGG hierarchy 15 
available via the R package “KEGGREST” (1.28.0) were selected (see tableS9) and 16 
genes mapping to these pathways were identified using “org.Hs.eg.db.” 17 
Pfam RNA-binding domains 18 
Classification of proteins into classical and non-classical RNA-binding proteins is based 19 
on their Pfam domain composition. We considered RRM, KH, DSRM, Piwi, DEAD, PUF, 20 
CSD, and zf-CCCH domains as classical. These were obtained from the PFAM.db R 21 
package (3.11.4). Furthermore, we considered as non-classical RNA-binding domains 22 
those Pfam-A domains robustly identified as RNA-binding by RBDmap  with at least 3 23 
peptides and RNA interactome capture (Castello et al., 2012; Castello et al., 2016). The 24 
classification is provided in Table S9. The proteins containing these domains were 25 
identified using org.Hs.eg.db.  26 
PubMed literature linking genes to viral infections  27 
To automatically query the NCBI Entrez Utilities REST API, the R package “rentrez” 28 












matching with a search query “(SYMBOL) AND (virus)” where SYMBOL is the gene 1 
name, such as EIF4E were retrieved. A minimum of five search results was considered 2 
a substantiated indication of a gene having a connection to virus-related literature. 3 
RNA sequencing analysis 4 
Strand-specific, poly(A) RNA-seq corresponding to SARS2-infected (MOI=2) Calu-3 5 
cells and controls from published work (Blanco-Melo et al., 2020) were downloaded from 6 
the Sequence Read Archive using “SRA toolkit “(2.10.8). Specifically, we analysed the 7 
following samples: Calu3 Mock 1 (GEO GSM4462348, SRA series SRX8089276, SRA 8 
run SRR11517744), Calu3 Mock 2 (GEO GSM4462349, SRA series SRX8089277, SRA 9 
run SRR11517745), Calu3 Mock 3 (GEO GSM4462350, SRA series SRX8089278, SRA 10 
run SRR11517746), Calu3 SARS-CoV-2 1 (GEO GSM4462351, SRA series 11 
SRX8089279, SRA run SRR11517747), Calu3 SARS-CoV-2 2 (GEO GSM4462352, 12 
SRA series SRX8089280, SRA run SRR11517748), Calu3 SARS-CoV-2 3 (GEO 13 
GSM4462353, SRA series SRX8089281, SRA run SRR11517749). Additionally, we 14 
processed the in-house generated RNA-seq in SARS2-infected WT and shDDX1 cells 15 
as detailed above. Raw reads alignment was performed via “STAR aligner” (2.7.3a) 16 
(Dobin et al., 2013), with splicing-aware settings, against human reference genome 17 
(GRCh38.99) and SARS-CoV-2 (NC_045512.2). Only uniquely aligned reads were used 18 
for downstream analyses. Mapped reads (exonic regions) counting was performed by 19 
“htseq-count” (0.11.3) in a strand-specific fashion. In order to assess the main driver(s) 20 
of variations across the RNA-seq samples, we performed a principal component 21 
analysis (PCA). First, we performed library size correction and variance stabilisation with 22 
regularized–logarithm transformation implemented in “DESeq2” (1.28.1) (Love et al., 23 
2014). This corrects for the fact that in RNA-seq data, variance grows with the mean and 24 
therefore, without suitable correction, only the most highly expressed genes drive the 25 
clustering. The 500 genes showing the highest variance were used to perform PCA 26 
using the “prcomp” function implemented in the base R package “stats” (4.0.2). Finally, 27 
differential expression analysis was performed using the R package “DESeq2” (1.28.1). 28 
“DESeq2” estimates variance-mean dependence in count data from high-throughput 29 
sequencing data and tests for differential expression based on a model using the 30 












Differential Exon Usage Analysis: We performed differential exon usage analysis 1 
using the DEXSeq R package (1.34.1) (Anders et al., 2012) to assess changes in 2 
transcript isoforms between SARS2-infected and uninfected cells (three replicates 3 
each). Briefly, we created a flattened exon annotation from protein coding transcripts of 4 
genes and lncRNAs using the dexseq_prepare_annotation.py python script 5 
accompanying the package. We then assigned the reads into this simplified annotation 6 
using dexseq_count.py provided with DEXSeq in a strand-specific fashion. Data was 7 
then tested for differential exon usage and estimated exon fold changes using the R 8 
package. DEXSeq models count data using a negative binomial (NB) distribution and 9 
generalized linear models (Anders et al., 2012). We considered exons that did not 10 
overlap multiple genes with adjusted p-value < 0.05 and absolute log2 fold change of at 11 
least 1 as significant. 12 
 13 
tRNA-ligase component and Unfolded Protein Response  genes: We used the 14 
GO.db (3.11.4) (Carlson 2020) and org.Hs.eg.db (3.11.4) Bioconductor R packages to 15 
identify GO terms and genes involved in tRNA splicing (GO:0072669, GO:0006388) and 16 
unfolded protein response (GO terms containing words ‘response to unfolded protein’ or 17 
‘unfolded protein response’, 21 terms in total). 18 
 19 
Xbp1 splicing and coverage: To plot Xbp1 coverage and splice junction usage, we 20 
used RSamtools (2.4.0),  IRanges (2.22.2), GenomicRanges (1.40.0) and 21 
GenomicAlignments (1.24.0) Bioconductor R packages to read and identify reads 22 
mapping to region on chromosome 22 corresponding to xbp1 gene, to calculate 23 
coverage in this region, and identify split reads spanning exon-exon junctions. To assess 24 
splicing at the xbp1 exon determining the main protein isoform (positions 28,796,122 25 
and 28,796,147 on chromosome 22), we identified reads that were spliced at these sites 26 
(resulting in long protein isoform) and those that were not (shorter protein isoform).  27 
Data wrangling and visualisation   28 
The “tidyverse suite” (1.3.0) was used for data wrangling in R, and “rtracklayer” (1.48.0)  29 
for manipulating gtf annotation files (Lawrence et al., 2009). Furthermore, we used the 30 
following R packages in creating the presented visualisation: “ggplot2” (3.3.2), “viridis” 31 














SUPPLEMENTARY LEGENDS 3 
Table S1:  Analysis of RBP dynamics in SARS-CoV-2 infected cells by cRIC. cRIC 4 
datasets were generated at 8 and 24 hpi. Related to Figure 1 5 
Table S2:  Analysis of the total proteome of SARS-CoV-2 infected or mock-infected cells. 6 
WCP analyses were generated at 8 and 24 hpi. Related to Figure 2 7 
Table S3:  Post-translational modification mapping to cellular RBPs. The cRIC data was 8 
cross-referenced to phospho-proteomic and ubiquinomic datasets reported by 9 
Bouhaddou et al., 2020; Klann et al., 2020; Stukalov et al., 2020. Related to Figure 2 10 
Table S4: Classification of RBPs by RNA-binding responses to SARS-CoV-2 infection. 11 
The different protein clusters were obtained by comparing the 8hpi/mock and 24hpi/8hpi 12 
fold-change of each RBP. Related to Figure 4 13 
Table S5: vRIC analysis of the SARS-Cov-2 RNA interactome. Related to Figure 5 14 
Table S6: cRIC and vRIC normalisation to the WCP. This table provides a ‘cross-link-15 
ability’ index that can be used to classify RBPs based on their ability to crosslink to RNA. 16 
Related to Figure 6. 17 
Table S7: RBP potential for regulatory roles in virus infected cells. List of RBPs reported 18 
in this study linked to the genome-wide screens that have reported their involvement in 19 
virus infection. Related to Figure 7. 20 
 21 
Table S8: Antibodies and Oligonucleotide primers used in this study. Related to Star 22 
Methods section.  23 
Table S9: List of GO-terms and KEGG pathways related to immune response and 24 
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• A third of the RBPome remodels upon SARS-CoV-2 infection 
• Viral RNPs include 139 cellular and 6 viral RBPs. 
• Inhibition of these cellular RBPs hampers SARS-CoV-2 infection. 
• The tRNA ligase complex is a key regulator of SARS-CoV-2. 
 
eTOC Blurb  
Kamel, Noerenberg, Cerikan and colleagues apply a multi-omic approach to identify 
the RNA-binding proteins that regulate SARS-CoV-2 infection. They discovered that 
the complement of RNA-binding proteins heavily remodels upon SARS-CoV-2 
infection. They also show that the viral RNA interacts with dozens of cellular and six 
viral RNA-binding proteins. These host-virus interactions are fundamental for SARS-
CoV-2 infection and have great potential for new therapeutic approaches against 
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Differential RNA expression in
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Proteins in SARS-CoV-2 cRIC
sh
D
D
X1
C
on
tro
l
ACTB
NCAP
DDX1
sh
FA
M
98
A
C
on
tro
l
FAM98A
RTCB
CGI-99
***
**
**
**
* **
Figure 7
E
SA
R
S-
C
oV
-2
, 2
4h
pi
10 µm
M
oc
k
DAPI
DDX1
dsRNA
DDX1 dsRNA 0
2
4
6
8
0.0 0.5 1.0
µm
Normalised AFU
0
2
4
6
8
0.0 0.5 1.0
µm
Normalised AFU
Fo
ld
 c
ha
ng
e 
(lo
g2
)
 R
N
A 
le
ve
ls
 (W
T 
vs
 s
hD
D
X1
)
−5.0
−2.5
0.0
2.5
5.0
DDX1
EIF2AK3SRPRB
FKBP14
IGFBP1
ASNS
CHAC1
ATF4
1ab
S3a
EM
7a8
N
10
SARS-
CoV-2
genes
tRNA-LC
genes
UPR
genes
All
genes
Up
No regulated
Down
SARS-CoV-2
SINV
